感染疾病相关一起同研究及授权契约:2019～2025年

本报告全面深入分析了全球领先的生物製药公司签署的传染病相关合作与许可协议，并提供前所未有的资讯取得管道。

本报告详细介绍了2019年至2025年间1,786项传染病相关协议。

主要的优点

• 2019年及以后的交易趋势
• 传染病合作与授权协议
• 透过基准分析确定交易市场价值
• 财务条款（预付款、里程碑付款、特许权使用费）
• 按公司、治疗领域和技术类型分类的合约目录
• 主要合约金额
• 最活跃的交易撮合者
• 查看每项协议的资产描述和条款协议
• 查阅合约文件 - 深入了解合约结构
• 尽职调查 - 评估伙伴对建议条款的适用性
• 节省数百小时的研究时间

合约分析可协助您对以下内容进行尽职调查：

• 具体授予或选择哪些权利？
• 协议具体授予合作伙伴哪些权利？
• 授予哪些独家权利？
• 合约的付款结构是什么？
• 收入和付款将如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 知识产权 (IPR) 将如何处理以及归谁所有？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 保密性和结果揭露将如何管理？
• 争议将如何解决？
• 合约在什么情况下可以终止？
• 如果公司所有权发生变更，合约将如何处理？
• 关于分授权和分包，双方约定的条款有哪些？
• 公司通常会包含哪些 "范本条款" ？
• 哪些 "范本条款" 会因合约当事人和合约类型而异？
• 公司要求以哪一法院为契约法的管辖法院？

目录

摘要整理

第1章 简介

第2章 感染疾病的契约动向

• 各年度的感染疾病领域的联盟趋势
• 各交易类型的联盟趋势
• 各产业部门的联盟趋势
• 各开发阶段的联盟趋势
• 各技术类型的联盟趋势
• 各治疗适应症的联盟趋势

第3章 感染疾病领域的财务条件分析

• 明确指示的财务条件
• 契约总额
• 预付款金
• 里程金
• 权利金费率

第4章 感染疾病:主要交易商与契约

• 最活跃的契约企业
• 最活跃的交易商清单
• 契约金额前几名的契约

第5章 感染疾病:契约文件的名录

• 可取得的联盟契约文件

第6章 感染疾病领域的契约:治疗标的

• 依治疗标靶分类的传染病合约
• 合约目录
• 依公司分类的合约目录
• 依技术类型分类的合约目录
• 交易类型定义
• 关于 Biopharma Research Ltd
• 当前合作
• 当前协议
• 近期目前合作报告标题

Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious diseases deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 1,786 infectious diseases deals from 2019 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of infectious diseases dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in infectious diseases dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the infectious diseases field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in infectious diseases dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of infectious diseases deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of infectious diseases deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in infectious diseases deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Infectious Diseases Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse infectious diseases collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Infectious Diseases Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of infectious diseases trends and structure of deals entered into by leading biopharma companies worldwide.

Infectious Diseases Collaboration and Licensing Deals includes:

• Trends in infectious diseases dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of infectious diseases deal records covering pharmaceutical and biotechnology
• The leading infectious diseases deals by value
• Most active infectious diseases licensing dealmakers

In Infectious Diseases Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Infectious Diseases Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious diseases dealmaking

• 2.1. Introduction
• 2.2. Infectious diseases partnering over the years
• 2.3. Infectious diseases partnering by deal type
• 2.4. Infectious diseases partnering by industry sector
• 2.5. Infectious diseases partnering by stage of development
• 2.6. Infectious diseases partnering by technology type
• 2.7. Infectious diseases partnering by therapeutic indication

Chapter 3 - Financial deal terms for infectious diseases partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for infectious diseases partnering
• 3.3. Infectious diseases partnering headline values
• 3.4. Infectious diseases deal upfront payments
• 3.5. Infectious diseases deal milestone payments
• 3.6. Infectious diseases royalty rates

Chapter 4 - Leading infectious diseases deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in infectious diseases partnering
• 4.3. List of most active dealmakers in infectious diseases
• 4.4. Top infectious diseases deals by value

Chapter 5 - Infectious diseases contract document directory

• 5.1. Introduction
• 5.2. Infectious diseases partnering deals where contract document available

Chapter 6 - Infectious diseases dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by infectious diseases therapeutic target
• Deal directory
• Deal directory - Infectious diseases deals by company A-Z 2019 to 2025
• Deal directory - Infectious diseases deals by technology type 2019 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Infectious diseases partnering since 2019
• Figure 2: Infectious diseases partnering by deal type since 2019
• Figure 3: Infectious diseases partnering by industry sector since 2019
• Figure 4: Infectious diseases partnering by stage of development since 2019
• Figure 5: Infectious diseases partnering by technology type since 2019
• Figure 6: Infectious diseases partnering by indication since 2019
• Figure 7: Infectious diseases deals with a headline value
• Figure 8: Infectious diseases deals with upfront payment values
• Figure 9: Infectious diseases deals with milestone payment
• Figure 10: Infectious diseases deals with royalty rates
• Figure 11: Active infectious diseases dealmaking activity since 2019
• Figure 12: Top infectious diseases deals by value since 2019